"Oncolytic Viruses" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumor-selective, replication competent VIRUSES that have antineoplastic effects. This is achieved by producing cytotoxicity-enhancing proteins and/or eliciting an antitumor immune response. They are genetically engineered so that they can replicate in CANCER cells but not in normal cells, and are used in ONCOLYTIC VIROTHERAPY.
Below are MeSH descriptors whose meaning is more general than "Oncolytic Viruses".
Below are MeSH descriptors whose meaning is more specific than "Oncolytic Viruses".
This graph shows the total number of publications written about "Oncolytic Viruses" by people in this website by year, and whether "Oncolytic Viruses" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Oncolytic Viruses" by people in Profiles.
Valenzuela-Cardenas M, Gowan C, Dryja P, Bartee MY, Bartee E. TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy. J Immunother Cancer. 2022 05; 10(5).
Thomas RJ, Bartee E. The use of oncolytic virotherapy in the neoadjuvant setting. J Immunother Cancer. 2022 04; 10(4).
Tang S, Shi L, Luker BT, Mickler C, Suresh B, Lesinski GB, Fan D, Liu Y, Luo M. Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model. Virol J. 2022 02 23; 19(1):32.
Iannuzzi CA, Indovina P, Forte IM, Di Somma S, Malfitano AM, Bruno M, Portella G, Pentimalli F, Giordano A. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines. Int J Mol Sci. 2020 Oct 04; 21(19).
Rahman M, Sawyer WG, Lindhorst S, Deleyrolle LP, Harrison JK, Karachi A, Dastmalchi F, Flores-Toro J, Mitchell DA, Lim M, Gilbert MR, Reardon DA. Adult immuno-oncology: using past failures to inform the future. Neuro Oncol. 2020 09 29; 22(9):1249-1261.
Gaspar N, Zambito G, Dautzenberg IJC, Cramer SJ, Hoeben RC, Lowik C, Walker JR, Kirkland TA, Smith TP, van Weerden WM, de Vrij J, Mezzanotte L. NanoBiT System and Hydrofurimazine for Optimized Detection of Viral Infection in Mice-A Novel in Vivo Imaging Platform. Int J Mol Sci. 2020 Aug 15; 21(16).
Flores EB, Aksoy BA, Bartee E. Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication. J Immunother Cancer. 2020 06; 8(1).
Sun F, Guo ZS, Gregory AD, Shapiro SD, Xiao G, Qu Z. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer. J Immunother Cancer. 2020 05; 8(1).
Bartee MY, Dryja PC, Bartee E. Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy. J Immunother Cancer. 2019 01 16; 7(1):11.
Russell L, Swanner J, Jaime-Ramirez AC, Wang Y, Sprague A, Banasavadi-Siddegowda Y, Yoo JY, Sizemore GM, Kladney R, Zhang J, Lehman NL, Ostrowski MC, Hong B, Caligiuri M, Yu J, Kaur B. PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance. Nat Commun. 2018 11 27; 9(1):5006.